- Forge Biologics has launched its FUEL platform to accelerate and improve AAV gene therapy manufacturing.
- The platform introduces new proprietary technologies, including the pEMBR 2.0 Ad helper plasmid and customized rep/cap plasmids.
Forge Biologics has introduced its new FUEL (Foundation for Unleashing Excellence in Life-Changing Therapies) manufacturing platform, aimed at providing AAV gene therapy developers with a faster and more efficient process for advancing their therapeutic programs. The platform’s launch includes technical advancements designed to support developers in reaching broader patient populations.
The FUEL platform includes Forge’s pEMBR 2.0 Ad helper plasmid, which is one of the smallest available on the market at 8.9kb, offering a higher safety profile and improved manufacturing efficiency. Additionally, the platform features modified rep/cap plasmids, enabling client-specific capsid sequences to be incorporated into Forge’s proprietary backbone. The HEK293 suspension Ignition cell line continues to be a core element of this production system.
“As a CDMO, we prioritise continuous innovation to deliver solutions that help our clients progress from discovery to clinical trials,” said John Maslowski, President and CEO of Forge Biologics. “The FUEL platform is the result of extensive research and provides flexibility with numerous optimisation packages.”
David Dismuke, Ph.D., Chief Technical Officer of Forge Biologics, added: “We are excited by the productivity gains we’re seeing, thanks to our team’s collaboration on the FUEL platform and our repeatable, high-titer manufacturing processes.”
Overview of outsourcing trends 
